SCHEMBL30878664

SCHEMBL30878664

COc1ccccc1Nc1ncc2c(C#C[Si](C(C)C)(C(C)C)C(C)C)cc(=O)n(-c3ccccc3)c2n1

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 10/20 0.51
BTK Q06187 1/20 0.45
CAMK2D Q13557 1/20 0.42
EGFR P00533 5/20 0.41
FGFR1 P11362 1/20 0.41
LRRK2 Q5S007 1/20 0.40
PRKDC P78527 1/20 0.40
ALK Q9UM73 1/20 0.40
JAK3 P52333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30878864 0.94 MAP4K1 (0.50) MAP4K1BTKEGFRLRRK2PRKDC
SCHEMBL30878675 0.93 MAP4K1 (0.48) MAP4K1BTKCAMK2DEGFRLRRK2
SCHEMBL30879341 0.92 MAP4K1 (0.47) MAP4K1BTKEGFRJAK3
SCHEMBL30878812 0.91 BTK (0.49) MAP4K1BTKEGFRJAK3
SCHEMBL30879087 0.90 ZAP70 (0.44) MAP4K1BTKEGFRFGFR1LRRK2
SCHEMBL30878814 0.90 FLT3 (0.47) MAP4K1BTKEGFRALKJAK3
SCHEMBL30879252 0.90 FLT3 (0.47) MAP4K1BTKEGFRLRRK2ALK
SCHEMBL30878821 0.89 EGFR (0.47) MAP4K1BTKEGFRFGFR1LRRK2
SCHEMBL30879138 0.89 BTK (0.43) MAP4K1BTKEGFRFGFR1JAK3
SCHEMBL30878843 0.88 BTK (0.47) MAP4K1BTKEGFRLRRK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612148-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER Cancer Research Technology Limited (GB) 2025-09-10 EP disclosed
WO-2024094963-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-05-10 WO disclosed